Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.51 |
| ▸ | PDE4A | P27815 | 2/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.51 |
| ▸ | TBK1 | Q9UHD2 | 4/20 | 0.51 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28909021 | 0.87 | GPR119 (0.53) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL1667168 | 0.87 | GPR119 (0.55) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL14453674 | 0.87 | GPR119 (0.58) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL3069360 | 0.86 | GPR119 (0.59) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL2776116 | 0.85 | GPR119 (0.69) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL17289802 | 0.85 | GPR119 (0.53) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL29826077 | 0.84 | GPR119 (0.49) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL8089497 | 0.83 | GPR119 (0.56) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL7655636 | 0.83 | GPR119 (0.52) | GPR119 | |
| SCHEMBL14087517 | 0.83 | GPR119 (0.67) | GPR119PDE4DPDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079693-B1 | ETHER DERIVATIVES DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HOFFMANN LA ROCHE (CH) | 2013-02-27 | — | — | EP | disclosed |
| US-7795437-B2 | Ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-09-14 | — | — | US | disclosed |
| EP-2079693-A1 | ETHER DERIVATIVES DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F. Hoffmann-Roche AG (CH) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008052899-A1 | ETHER DERIVATIVES DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-08 | — | — | WO | disclosed |
| US-20080103174-A1 | ETHER DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103174-A1 | ETHER DERIVATIVES | GABRE, BDNF, ADH1A | GPR119 887/4885PDE4D 1967/4885PDE4B 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.